Merck to buy Terns (TERN) NASDAQ for $53 on 25 Mar 2026: earnings catalyst for TERN stock

TERN stock is trading sharply higher intraday after reports that Merck will acquire Terns Pharmaceuticals, Inc. (TERN) on the NASDAQ for $53.00 per share and with an earnings report due tonight. The shares are at $52.78, up $3.16 or 6.38%, on volume of 65,488,481 as traders price the deal and watch tonight’s results (earnings announcement scheduled 2026-03-25 16:00 EDT). This earnings spotlight looks at how the Merck offer, clinical progress and key metrics link to the stock move and short-term outlook for U.S. investors trading in USD.

TERN stock: Deal and earnings context

The most important driver today is Merck’s cash offer of $53.00 per share, reported by multiple outlets and reflected in intraday flows. Reports show Merck values Terns at about $6.70B, a direct valuation cap on market expectations ahead of Terns’ earnings release tonight at 16:00 EDT. The acquisition talk and the upcoming earnings create a binary near-term setup for TERN stock for traders focused on catalysts.

TERN stock: Intraday price action and volume

Terns Pharmaceuticals opened at $52.63, with a day low of $52.59 and a day high of $52.79 while volume surged to 65,488,481 versus an average of 2,164,449, signaling heavy trade. The stock is near the proposed offer price, compressing upside for takeover arbitrage and raising volatility for intraday traders.

TERN stock: Fundamentals and valuation

Terns remains a clinical-stage biotech in the U.S. healthcare sector with trailing EPS -1.02 and a negative PE of -49.02, reflecting losses and early-stage R&D spending. Cash per share stands at 3.22 and book value per share is 3.10, while the company shows a current ratio 19.52, highlighting a strong liquidity position. These fundamentals explain the wide range in valuation and why an acquisition premium matters more than typical multiples.

TERN stock: Technical setup and market signals

Momentum indicators show short-term strength: RSI 72.57 (overbought) and MACD histogram 0.39, with ATR 2.52 indicating elevated intraday swings. Price is above the 50-day average $39.67 and 200-day average $20.49, confirming a strong uptrend. The gap between current volume and average volume underlines institutional interest ahead of the earnings and deal news.

TERN stock: Meyka AI rating and forecast

Meyka AI rates TERN with a score out of 100: 72.87 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term quarterly target of $56.71, implying an upside of 7.47% versus the current price $52.78. Forecasts are model-based projections and not guarantees.

TERN stock: Analyst consensus and deal risks

Street coverage skewed bullish before the deal with 14 Buy ratings and a consensus score of 4.00. The Merck approach reduces binary clinical risk but introduces regulatory and integration execution risk. Key risks remain clinical trial outcomes for TERN-701 and timing for deal close expected in Q2 2026.

Final Thoughts

Key takeaways: Terns Pharmaceuticals, Inc. (TERN) on NASDAQ is trading at $52.78 intraday as Merck’s reported $53.00 per-share offer and tonight’s earnings create a clear catalyst. The stock’s trading volume 65,488,481 versus average 2,164,449 shows heavy interest and a compressed arbitrage window near the proposed price. Fundamental metrics—EPS -1.02, PE -49.02, cash per share 3.22—still reflect clinical-stage risk, but the acquisition premium materially lowers valuation uncertainty. Meyka AI’s model projects $56.71 as a near-term quarterly forecast, an implied upside of 7.47% from the current price; forecasts are model-based projections and not guarantees. For intraday traders and event-driven investors, focus on the formal deal announcement, tonight’s earnings details, and regulatory commentary. For longer-term investors, the Merck bid and clinical pipeline change the risk profile, but integration and regulatory timelines will determine realized value. Visit our detailed market page for TERN stock at Meyka stock page. For more on the acquisition and market reaction see reporting from CNBC and Reuters. Meyka AI provides this AI-powered market analysis to help frame near-term trades and strategic portfolio decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.